Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Identification of persister cells and evolution of tumor clones during immunotherapy and at minimal residual disease timepoints decoded by single-cell whole-genome sequencing in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

CKCatherine M. KetchamSMSophie MagidsonSMShonali Midha

Discussion

Loading...

Member takes

Overview

Longitudinal analysis reveals immunotherapy impacts tumor evolution and minimal residual disease in multiple myeloma.

Key Points

  • Tumor clones evolved during immunotherapy targeting minimal residual disease, largely influenced by low CD38 expression.
  • Single-cell whole-genome sequencing assessed tumor cells across patients, revealing clonal heterogeneity not seen in bulk analyses.
  • Sequencing depth of 60X was utilized for whole-genome studies, identifying persistent tumor cells post-therapy.
  • Research underscores the importance of scWGS in tracking myeloma evolution, guiding future therapeutic strategies.

Cite This Study

Ketcham et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5ffhttps://doi.org/10.1182/blood-2025-3930
View Full Paper
Ask AI
Bookmark
Share